Ferric carboxymaltose (Ferinject ®), a novel iron complex that consists of a ferric hydroxide core stabilized by a carbohydrate shell, allows for controlled delivery of iron to target tissues. Administered intravenously, it is effective in the treatment of iron-deficiency anaemia, delivering a replenishment dose of up to 1000mg of iron during a minimum administration time of 15 minutes. Results of several randomized trials have shown that intravenously administered ferric carboxymaltose rapidly improves haemoglobin levels and replenishes depleted iron stores in various populations of patients with iron-deficiency anaemia, including those with inflammatory bowel disease, heavy uterine bleeding, postpartum irondeficiency anaemia or chronic kidney disease. It was well tolerated in clinical trials. Ferric carboxymaltose is, therefore, an effective option in the treatment of iron-deficiency anaemia in patients for whom oral iron preparations are ineffective or cannot be administered. © 2009 Adis Data Information BV. All rights reserved.
CITATION STYLE
Lyseng-Williamson, K. A., & Keating, G. M. (2009). Ferric carboxymaltose: A review of its use in iron-deficiency anaemia. Drugs. https://doi.org/10.2165/00003495-200969060-00007
Mendeley helps you to discover research relevant for your work.